SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SANGAMO THERAPEUTICS, INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
Community
Notes and questions about Sangamo Therapeutics from other investors
No posts about SGMOQ yet
Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.